Comparison of morning vs evening dosing of the latanoprost/timolol maleate fixed combination (Xalacom) on intraocular pressure control in primary open angle glaucoma. -Pilot Study
- Conditions
- primary open angle glaucoma
- Registration Number
- JPRN-UMIN000011275
- Lead Sponsor
- Department of Ophthalmology, Kanazawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
(1) Pregnant and lactating women, the women who desired of the pregnancy. (2) Patients who have difficulty or are unable to undergo fundoscopy (severe cataract, etc.). (3) Patients with active external ocular diseases, ocular inflammation or infection. (4) Patients with myopia of at least 9.0D spherical equivalent and more than hyperopia 9.0D spherical equivalent (5) Patients with anisometropia more than 3D spherical equivalent (6)Patients with any corneal abnormality or other condition preventing reliable applanation tonometry. (7) Patients with history of refractive surgery, glaucoma surgery (SLT, trabeculotomy, trabeculectomy etc), vitreous surgery or retinal detachment surgery. (8) Patients with history of surgery for cataract within 3 months before the study. (9)Patients expected to require operation for an eye disease during the study period. (10)Patients with serious renal impairment (nephrotic syndrome, acute renal failure, chronic renal failure, etc.) (11) Patients with hepatic function disorder. (12) Patients with bronchial asthma or its history. (13) Patients with bronchospasm or serious chronic obstructive pulmonary disease. (14) Patients with cardiac failure, sinus bradycardia, atrioventricular block (second and third degrees), or cardiogenic shock. (15) Patients with right cardiac failure due to pulmonary hypertension. (16) Patients with congestive cardiac failure. (17) Patients with diabetic ketoacidosis and/or metabolic acidosis. (18)Patients with poorly controlled diabetes mellitus. (19)Patients with a anamnestic history of hypersensitivity to any ingredients of the investigational product. (20) Patients who has received administration of the adrenocortical steroid agent (except for local skin administration other than around eyes). (21) Patients whom doctor judged to be ineligible for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intraocular pressure lowering level
- Secondary Outcome Measures
Name Time Method Adherence Safety